The Bracken Group Blog — The Bracken Group | Colin G. Miller (2)

Colin G. Miller

Ph.D, FIPEM, CSci, has been a leader in the development of medical imaging in clinical trials. He has more than 30 years in medical and scientific consulting. He also provides strategic development for the regulatory pathway and FDA interaction with respect to new diagnostics and end points in therapeutic clinical development. He has over 70 peer reviewed publications, 3 patents and published three books including “Medical Imaging in Clinical Trials” by Springer.

Recent Posts

1 June 2019

Are Placebo-Controlled Trials in Osteoporosis Ethical?

Colin G. Miller

1 June 2019

The Use of Biomakers and PET in Early Alzheimer's Disease Diagnosis

Colin G. Miller

1 June 2019

How Time, Quality, & Cost Metrics Affect Clinical Trials and Programs

Colin G. Miller

1 June 2019

EOS Imaging System is an Emerging New Technology

Colin G. Miller

1 June 2019

Five Things Every Data Manager Should Know When It Comes to Medical Images in Clinical Trials

Colin G. Miller

1 June 2019

Monitoring Skeletal Integrity for Safer Diabetes Therapies

Colin G. Miller

1 June 2019

Five Documents Critical for the Success of Clinical Trials with Medical Images

Colin G. Miller

16 January 2019

The Bracken Group Responds to the FDA New Draft Guideline on Clinical Trial Compliance Proposing Novel Technology from Bracken Data

Colin G. Miller